Life Sciences — Active pipeline
Programs centered on defined patient populations, focused development strategies, and substantial unmet need.
| Program | Indication | Candidate | Regulatory milestone |
|---|---|---|---|
| MGAM-003Classic PMD | Classic Pelizaeus-Merzbacher diseaseRare pediatric disease | Clemastine fumarate | Rare Pediatric Disease Designation granted |
| Gradus Neurology | Unannounced | Unannounced | Pre-Submission filed with FDA |
- The program
- UnannouncedA program in neurology. Its indication, approach and timing are not yet announced. About Project Gradus
- Regulatory status
- MGAM LLC filed a Pre-Submission with the U.S. Food and Drug Administration, which received it on November 10, 2026 (Q263830). A Pre-Submission asks FDA for written feedback on a planned study. It is not an approval, a clearance or permission to begin one.